SkillCell is a biotech company with the slogan "Biology-based, objective decision-making support tools". Founded in 2017, the company aims to revolutionize biochemical analysis for diagnostics by prioritizing patient ease of use. SkillCell has developed a CE-marked urine test for insulin-resistance identification (IDIR) and a CE-marked saliva test for Covid-19 (EasyCOV), both of which contribute to rapid and accessible diagnostics. The company's network includes global experts in multiple locations, and it has a strong public-private partnership with Sys2Diag, a CNRS laboratory. SkillCell's focus is on developing technologies to provide reliable answers, new choices, and opportunities for users' lives. They are committed to improving everyday lives and surroundings through their simplicity-centered approach. Currently, there is no public information available regarding the last investment and investors for SkillCell.
SkillCell
Biology-based, objective decision-making support tools
France
9 employees
Biotechnology, Health Care
General Information
Get notified when SkillCell moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track SkillCell
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
France Market
Biotechnology
About SkillCell
Taxonomy: molecular biology, synthetic biology, rapid tests, microfluidics, precision medicine, preventative medicine, diagnostics, IVD, insulin resistance, diabetes, one health, animal health
No funding data available for SkillCell yet.
Get notified when SkillCell raises fundingSkillCell Alternatives & Competitors
Lateral Flow Rapid Tests and more
FAQ About SkillCell
Don't just browse. Track.
Signal Tracker monitors SkillCell and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.